GA-ASI Performs Cold Weather Validation Using MQ-9B
Validation Flight Satisfies the Cold Weather Operational Capability Needs for Nordic Countries...
Globe Newswire25-02-2023, 01:18
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00
